| |
Number
|
|---|
|
Sex
|
|
Male
|
46
|
|
Female
|
14
|
|
Age (years)
|
|
Median
|
70
|
|
Range
|
32–81
|
|
Histological type
|
|
Adenocarcinoma
|
27
|
|
Squamous cell carcinoma
|
27
|
|
Pleomorphic carcinoma
|
3
|
|
Adenosquamous cell carcinoma
|
2
|
|
Large cell carcinoma
|
1
|
|
Size of primary tumor (mm)
|
|
Median
|
35
|
|
Range
|
13–88
|
|
Clinical T status
|
|
T1
|
16
|
|
T2
|
29
|
|
T3
|
14
|
|
T4
|
1
|
|
CEA (ng/mL)
|
|
Median
|
4.8
|
|
Range
|
1.5–152.2
|
|
SCC (ng/mL)
|
|
Median
|
0.8
|
|
Range
|
0.0–19.7
|
|
CYFRA (ng/mL)
|
|
Median
|
2.48
|
|
Range
|
0.59–53.08
|
|
FDG-PET
|
|
Number of patients
|
35
|
|
Median of SUVmax
|
6
|
|
Range of SUVmax
|
0–22.78
|
|
FDG-PET/CT
|
|
Number of patients
|
25
|
|
Median of SUVmax
|
11.45
|
|
Range of SUVmax
|
1.90–52.60
|
|
Surgical approach
|
|
VATS
|
23
|
|
Thoracotomy
|
20
|
|
Conversion (VATS to thoracotomy)
|
17
|
|
Operative procedure
|
|
Pneumonectomy
|
7
|
|
Lobectomy
|
51
|
|
+ bronchoplasty
|
3
|
|
+ angioplasty
|
1
|
|
+ bronchoplasty & angioplasty
|
2
|
|
Segmentectomy
|
2
|
|
Pathological T status
|
|
pT1
|
15
|
|
pT2
|
29
|
|
pT3
|
14
|
|
pT4
|
2
|
|
Pathological N status
|
|
pN0
|
23
|
|
pN1
|
22
|
|
pN2
|
15
|
|
Pathological stage
|
|
IA
|
4
|
|
IB
|
12
|
|
IIA
|
14
|
|
IIB
|
6
|
|
IIIA
|
23
|
|
IIIB
|
1
|
